{"name":"PharmaEssentia Japan K.K.","slug":"pharmaessentia-japan-k-k","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"P1101","genericName":"P1101","slug":"p1101","indication":"Immune thrombocytopenia (ITP)","status":"phase_3"}]}],"pipeline":[{"name":"P1101","genericName":"P1101","slug":"p1101","phase":"phase_3","mechanism":"P1101 is a recombinant human thrombopoietin (TPO) analog that stimulates platelet production by binding to the thrombopoietin receptor.","indications":["Immune thrombocytopenia (ITP)","Chemotherapy-induced thrombocytopenia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNR3lqZFItRzBjX2VUSHB6TEtGYXRLOGNtM3RRU212SmgxRFNLT0NRYTBfMU5tWVMwbUtaYjJyd3RvWDRhUkFxRDhQaThTS2FIaHBIcURGaW9xd0FKbnoteHRlb1Z3UEhnWjFGT19IdTEzZVh0bWZocGpXWGExUFhXOURsNFdPNDRrYXpObDZOMEREc0FnY3FBU3lNMVo3MHJXQ3lrZHgxNXdJMnpsZmhKMGt5Tkx6RFdHQXZv?oc=5","date":"2026-03-03","type":"regulatory","source":"BioSpace","summary":"PharmaEssentia Announces Japan Approval of High-Dose Dosing Regimen for BESREMi® - BioSpace","headline":"PharmaEssentia Announces Japan Approval of High-Dose Dosing Regimen for BESREMi®","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQN2lIenJwTDAxYnJhX3lxZnpwRXRibEoxV01KVEFLU09qQ2RoMXpUNklRSFUwd3lLQWN4ZkZ4by0zcWI1d2xfRmo3ZXphTE1IM0RnN3poWlRjNkRySk05ak9yaUh3bWNyMnBOS1ZUdHdwSlgwUnVJX3NRTUFKOWdkeUtUM3RBeW03SHZqbmVFc21NejVyb0hFOUN4TG11aU8tQzZTQ1V2Wl9YUQ?oc=5","date":"2026-02-11","type":"pipeline","source":"BioSpace","summary":"PharmaEssentia Shores Up Supply With $46M Investment in Puerto Rico Plant - BioSpace","headline":"PharmaEssentia Shores Up Supply With $46M Investment in Puerto Rico Plant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE43YWZmalNrYmNvemxkU2tUWnVfLUpLdDZ4dG1MMTB3djVVSERoWTJiR3FiYzVDZ0gzdVdTVW9aS0w1eERyWGc5YUZVSm5EdEhMTEN1T0plYVpBc3JlVzVqeWZWa0VHLWMw?oc=5","date":"2025-09-09","type":"trial","source":"Wiley Online Library","summary":"Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study - Wiley Online Library","headline":"Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxPSGhOWk5FYmF3bUUzV1FWZEhfQ1hjYnZlWXVYTzB6dlFuSmxFVzdRbnJWSS1MZnptcXpLMGVicFFRa2VFQ2ZXN0oybFFPclpHUkpzdEt4OVB2dmNvYTFDTzQzcGozTzRFUnpXN1pwaEpzZ3J1TjJaXzlpRHBtaVpxQzhQeXJER2ZFOFBDblRfN1B2MEtsc0Y0R0FqWWNUaktuYVRDaWJ2YkxNcEpfZ0RGdEFxZUpHblBrcHBTVkxwX2ZUbnpta3Q5Zkw0Sm1oblRkdUpDaE5BX2VZUHJyOS1iclU4dXlSdmZVS3RhWmpPNTlWX3pPdnF4UVpCdUR4b3dJdzU3Q0VhbE5kZ3FnNE8xLXhNbUZtdw?oc=5","date":"2025-03-05","type":"pipeline","source":"BioSpace","summary":"PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage - BioSpace","headline":"PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peg","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxPbEJsQTJ0MFJJSlgtM3VKeGZMVHo0Tk5xdElzMDlCMkVnVllFeUJoYi04RjdtZFJBV3JiM3BtUU1nd3gyZWZCYlp2QURCdXJBV1F6d20yR2Rna25lTENrWHB1YmFJb0NYb0NfTFFYVVI2SHE4eFo3czVnSEFVZWR1ay1rTjNKX3p6QnFXUlJSdDNFQlBoSGFHTWFDVUsyNWUybjRYNXZGb0hkc3VKWU1wUjlaS1UwUUZvWGtmMldRQ1psN0VhaUlvWVZWa2VBWVFyUWF4RlFJR2k5dVQyWFRiOExPQmJJR3N2Mk9kcXQ4d3NHdDJRRlZJT1VVYWhiOTQ4bkVnM2JRMnhNemVMcE0wM2d6Y2NjRURqZjlEUg?oc=5","date":"2025-01-06","type":"trial","source":"BioSpace","summary":"PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia - BioSpace","headline":"PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9YNUFubFU3eFk4QmlDaXRVbGNiOU1EVENHUW53UkxqV1dpandtSkZNNC10dmZYNDJLaUtsMlZHSkdoY3ROWTJRNDduYjVBMy1DVHZDYnVULWxEWGtSNlVv?oc=5","date":"2024-07-11","type":"pipeline","source":"nature.com","summary":"Ropeginterferon alfa-2b shows anti-polycythaemia vera activity without causing clinically significant anaemia - nature.com","headline":"Ropeginterferon alfa-2b shows anti-polycythaemia vera activity without causing clinically significant anaemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE5tWGhEbnhiSEw2Wkk3bF9tRWdVWGFhd2h5WTVicHZJYjRNZEMyVEw1Z2t6Rnhzb3Z1bnBleDVjNzNZcWN2aWx4Y0hvZDdMUTBmOUJPdUN3?oc=5","date":"2024-04-09","type":"pipeline","source":"Yahoo! Finance Canada","summary":"PharmaEssentia Corporation (6446.TW) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"PharmaEssentia Corporation (6446.TW) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxON0thdkRVVVRYUmNERU9pbklicGZtc050SmVZeG5jbDhwOXlFNW9QSWJkY0QwMGgtTDFicHdidERRdUhENmM3UXlYeUJkWkJGNjMxTDlsMkN0YUxMUjB2enlCQmFrRTBXLURjcE5oVDBsaVItMkZfa1VCcUJqZVh4Mk03Y24yVlFnY2c?oc=5","date":"2023-06-05","type":"pipeline","source":"Pharmaceutical Technology","summary":"PharmaEssentia choses Pint-Pharma to commercialise BESREMi - Pharmaceutical Technology","headline":"PharmaEssentia choses Pint-Pharma to commercialise BESREMi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxOb1BlM3dqUS1QS1FzaUNkbUpTeUxaQk5DZ2ZTU1BrcURxbl9QODF5OTRyaXU4UFdhT3RtNHpmbVZqSFFLUHF3enhMN1duOVNRMnlELThGZTNxZUVWb0xuV3lWaFJ2endxdnRQSWFoZGEtSWdzTndXa2s5NlgzNTIzU0NQcFhaVDZyUDN6ZmtMak92ejVWdmJjbVpVc0VfMjFEd0gzTjFpRGxrc3h1YWN0VEE5ZkZCdllsdGhUNmR6RzB1RFVUbmZabmZnUXE2bXRLajNwUTFiNEVuLXdldXcwRG5aRk9DZVRrUXFNTXN2dDZhUEpxczVQd1M0dmJiUE5a?oc=5","date":"2023-06-02","type":"deal","source":"businesswire.com","summary":"PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi - businesswire.com","headline":"PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQTXY0eUlvRUxic2dGNEN3d1JKaHoxRDgzcy03a0sxRHAyYW8tazg5eXhWZGpERFlLR3NjcE8xZ29Ick1lbVd2My1abms1UVl4c3ZTSmN5cmRZaVBPcURHeGxnY0JFSUhoSm1KZFVvZjNEN3EyLTVwdTl0ZzU5RFBWNEdHREI4TkN0VGZDSjVJR1IwYUtUTGJDOEJtaTVtd2Z2NjFWaVhBLTQ2b2tYWjNN?oc=5","date":"2023-04-27","type":"pipeline","source":"BioWorld News","summary":"Pharmaessentia raises $462M in GDR offering to expand global footprint - BioWorld News","headline":"Pharmaessentia raises $462M in GDR offering to expand global footprint","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}